Aethlon Medical, Inc. AEMD 深 沪
已收盘 04-02 16:00:00 美东时间
2.12
-0.030
-1.40%
华盛通- 最 高2.22
- 今 开2.22
- 成交量 1.91万股
- 最 低 2.00
- 昨 收 2.15
- 总市值 332.65万
- 52周最高 35.20
- 市盈率 静 --
- 换手率 1.22%
- 52周最低 1.36
- 委 比 77.99%
- 总股本 156.91万
- 历史最高 432000.00
- 量 比 1.16
- 振 幅 10.23%
- 历史最低 1.36
- 每 手 1
- 风险率 10.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aethlon Medical Announces Independent Data Safety Monitoring Board Completes Its Safety Review For AEMD-2022-06; Finds No Safety Concerns; Recommends Third And Final Cohort
Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that
03-24 20:13
Aethlon Medical says all pre-funded warrants have been exercised
Aethlon Medical says all pre-funded warrants have been exercised Aethlon Medical said recent exercises of certain pre-funded warrants increased its common shares outstanding to 1,569,110 as of the close of business on March 16, 2026. The company said all previously outstanding pre-funded warrants ha
03-17 21:15
Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and ...
03-12 20:01
**Aethlon Medical CEO Jim Frakes to present at Life Sciences Investor Forum**
**Aethlon Medical CEO Jim Frakes to present at Life Sciences Investor Forum** Aethlon Medical, Inc. (Nasdaq: AEMD) will present live at the Life Sciences Investor Forum on March 12, 2026, from 1:00–1:30 p.m. ET. Registration is available at https://www.globenewswire.com/Tracker?data=OZ2dpMKG4_eO01DP
03-06 21:35
Aethlon Medical to Present at Emerging Growth Conference
Aethlon Medical to Present at Emerging Growth Conference Aethlon Medical Inc. (Nasdaq: AEMD) will present at the Emerging Growth Conference on February 25, 2026, from 12:30 to 1:00 PM ET, featuring a live interactive session with CEO and CFO Jim Frakes and a Q&A. Event materials and links: https://d
02-23 21:03
Aethlon Medical signals faster clinical trial enrollment amid Hemopurifier advancements
Earnings Call Insights: Aethlon Medical (AEMD) Q3 2026 Management View James Frakes, CEO and CFO, stated that Aethlon Medical continues to execute its strategy of advancing the Hemopurifier platform w...
02-13 11:15
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
Aethlon Medical Files For Common Stock Offering Of $15M
$15,000,000 Common Stock From time to time, we may offer and sell shares of our common stock, par value $0.001 per share, with total gross proceeds of up to $15,000,000. This prospectus provides a general
2025-12-24 04:10
Aethlon Medical Announces Publication Of Pre-Clinical Long COVID Study On bioRxiv
Results Support the Further Investigation of the Hemopurifier in Long COVIDSAN DIEGO, Dec. 2, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to
2025-12-02 21:26
Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study
Aethlon Medical Inc. has announced the publication of preclinical data demonstrating that the GNA affinity resin in its Hemopurifier® device binds to extracellular vesicles (EVs) in plasma samples fro...
2025-12-02 21:02
